LIVMARLI Now Approved in Japan for ALGS and PFIC
LIVMARLI is the first and only treatment available for cholestatic pruritus in patients with Alagille syndrome and ...
Zacks Investment Research on MSN6d
Mirum's Heavy Dependence on Livmarli for Revenues Remains a Woe
Mirum Pharmaceuticals’ MIRM lead product, Livmarli (maralixibat), an orally administered ileal bile acid transporter (“IBAT”) ...
Mirum Pharmaceuticals: Set Fair For Share Price Momentum - Reversing My Sell Call
Mirum Pharmaceuticals stock surged 25% and how LIVMARLI drives growth. Explore future prospects with Volixibat. Click here to ...
pharmaphorum3d
Ipsen's Alagille drug backed by CHMP again, with new name
The once-daily, non-systemic ileal bile acid transport (IBAT) inhibitor was recommended for approval by the EMA's human medicines committee, the CHMP, in July 2023 for this indication under the ...
Business Wire8d
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with ...
Business Wire1mon
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025
A replay of this webcast will be available for 30 days. About Mirum Pharmaceuticals LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults.